PhaseRx Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2016	FY 2015	FY 2014
Period Ending	Sep '17 Sep 30, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014
Revenue	-	-	0.38	1.2
Revenue Growth (YoY)	-	-	-68.75%	-
Gross Profit	-	-	0.38	1.2
Selling, General & Admin	4.7	11.67	1.3	1.93
Research & Development	8.34	6.66	4.88	4.86
Operating Expenses	13.04	18.33	6.18	6.79
Operating Income	-13.04	-18.33	-5.81	-5.59
Interest Expense	-0.94	-2.06	-1.65	-1.37
Interest & Investment Income	0.09	0.06	-	-
Other Non Operating Income (Expenses)	-	0.19	0.08	0.11
Pretax Income	-13.89	-20.14	-7.38	-6.85
Net Income	-13.89	-20.14	-7.38	-6.85
Net Income to Common	-13.89	-20.14	-7.38	-6.85
Shares Outstanding (Basic)	12	8	1	0
Shares Outstanding (Diluted)	12	8	1	0
Shares Change (YoY)	147.73%	1349.71%	18.78%	-
EPS (Basic)	-1.19	-2.68	-14.21	-15.68
EPS (Diluted)	-1.19	-2.68	-14.21	-15.68
Free Cash Flow	-12.84	-9.98	-6.09	-4.91
Free Cash Flow Per Share	-1.10	-1.33	-11.74	-11.25
Gross Margin	-	-	100.00%	100.00%
Operating Margin	-	-	-1548.53%	-465.92%
Profit Margin	-	-	-1967.20%	-570.75%
Free Cash Flow Margin	-	-	-1625.07%	-409.50%
EBITDA	-12.96	-18.19	-5.48	-5.08
D&A For EBITDA	0.08	0.14	0.33	0.51
EBIT	-13.04	-18.33	-5.81	-5.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.